|Day Low/High||115.40 / 115.89|
|52 Wk Low/High||88.76 / 116.60|
Wall Street ends lower, falling into the red in the final hour, after the Federal Reserve's commits to further monetary tightening this year.
Monsanto reported better than expected 2017 earnings results.
Stocks lose highs Wednesday after the minutes were released from the Federal Reserve's most recent meeting.
Wall Street clocked solid gains after a strong reading on private payrolls bode well for the official jobs number out at the end of the week.
Stocks extend gains on Wednesday after a strong reading on private payrolls foreshadows a solid U.S. jobs number for March.
With half of its fiscal year 2017 complete, Monsanto Company (NYSE: MON) announced strong second quarter and first six months results.
U.S. stock futures are mixed Wednesday as investors await the release of the minutes from the Federal Reserve meeting in March, and a snapshot on the U.S. labor market.
Overall expectations for the S&P 500 are for earnings increase of over 9% year on year for the first quarter.
ChemChina and Switzerland's Syngenta win conditional approval from the European Commission for their $43 billion Wednesday.
On Wednesday, April 5, investors await quarterly earnings from Walgreens WBA, Bed Bath & Beyond BBBY and Monsanto MON.
ChemChina must sell its U.S. paraquat, abamectin and chlorothalonil crop protection businesses to California agrochemical company AMVAC.
Jim Cramer is watching Monsanto earnings, but for a read on its deal with Bayer rather than the actual results.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said investors should watch Monsanto's MON earnings for the status of its pending merger with Bayer.
Wall Street enters a new week and new quarter on Monday with stocks at or close to all-time records set at the beginning of March.
Wall Street's pro-business agenda could suffer collateral damage, as infighting among Republicans grows worse. Here's how to trade in the days ahead.
Antitrust experts say DOJ and FTC will need to tune out the president's Twitter feed.
The amazing first quarter didn't rely just on Trump.
Monsanto Company (NYSE: MON) announced it will issue the company's financial results for its fiscal 2017 second quarter on Wednesday, April 5, 2017, prior to market open.
Investment manager Marcato Capital Management says the changes to the board 'do not go far enough,' even though one of the nominees came from its dissident slate.
The details matter in this case.
Monsanto's former VP, Michael Taylor was head of the FDA under Obama.
If you think the chemicals sector is primed for further highs, this is a good way to play.
The move is intended to make their $66 billion merger more palatable to regulators.
European stocks were weaker and bonds higher as unease returned to markets.
Bayer isn't expecting their deal for Monsanto to be derailed by regulatory issues, despite recent delays.
Bayer shares fell after the drugmaker posted solid full-year earnings but said its crop sciences unit would see modest growth in 2017 as it completes its $66 billion Monsanto takeover.
A week full of financial reports continues, as Bayer and Lloyds post full-year earnings
European stocks tested multi-month highs Wednesday after better-than-expected business sentiment data from Germany and an upgrade to the fourth quarter pace of growth in the United Kingdom.